Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Six months ended April 30, 1997 (Fiscal Year 1997, Q2).
Business Overview: The Company operates in three primary segments: CooperVision, Inc. (CVI) manufacturing contact lenses; CooperSurgical, Inc. (CSI) manufacturing gynecology products; and Hospital Group of America, Inc. (HGA) providing psychiatric and behavioral health services.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended Apr 30, 1997 | Six Months Ended Apr 30, 1996 |
|---|---|---|
| Net Operating Revenue | $62,039 | $49,024 |
| Income from Operations | $10,379 | $5,774 |
| Net Income | $8,683 | $3,461 |
| Earnings Per Share | $0.72 | $0.30 |
| Cash Flow from Operations | $295 | $(7,358) |
| Cash and Equivalents (Ending) | $1,538 | $1,894 |
| Total Debt (Current + Long-term) | $47,896 | $48,764 |
Margins: Consolidated gross margin on products was 70% for the six months ended April 30, 1997, compared to 70% in the prior year. HGA service profit margin improved to 10% from 3% in the prior period.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenue increased 27% ($13 million) driven by a 28% increase in product sales and a 24% increase in service revenue.
- Profitability: Net income increased 151% ($5.2 million) primarily due to higher operating income and a $830,000 reduction in the deferred tax asset valuation allowance.
- Acquisitions: The Company acquired Natural Touch'r' (cosmetic lenses) in March 1997 and Marlow Surgical Technologies (gynecology products) in April 1997. These contributed significantly to CSI revenue growth.
- Debt Restructuring: On April 9, 1997, the Company redeemed or converted $9.3 million of Convertible Subordinated Reset Debentures into common stock, eliminating future interest on this instrument.
- Cash Flow: Operating cash flow improved by $7.7 million year-over-year, turning from a $7.4 million outflow in 1996 to a $0.3 million inflow in 1997.
Guidance, Outlook, and Risks
- Debt Refinancing: The Company has signed a commitment for a $50 million senior secured revolving credit facility with KeyBank, expected to close in the fourth fiscal quarter. This is anticipated to save approximately $1.2 million annually in interest.
- Future Projections: The Company has explicitly stated it will not update prior sales, revenue, or earnings projections at this time, citing the availability of a shelf registration for equity offerings.
- Regulatory Risks: The FTC requires the Company to develop manufacturing capabilities or find a third-party manufacturer for the Natural Touch'r' line within 18 months (extendable to 42 months) or face divestiture.
- Liquidity: Management anticipates positive operating cash flows for the remainder of fiscal 1997. The Company plans to utilize its line of credit and potential equity offerings to fund acquisitions and general corporate purposes.
Investor Verification Checklist
- FTC Compliance: Verify the timeline and progress regarding the FTC divestiture order for the Natural Touch'r' manufacturing capabilities.
- Debt Refinancing Closing: Confirm the closing date and final terms of the $50 million KeyBank credit facility to validate projected interest savings.
- Acquisition Integration: Monitor the integration of Marlow Surgical Technologies and the revenue contribution of Natural Touch'r' to ensure they meet growth expectations.
- Equity Dilution: Review the impact of the $9.3 million debenture conversion and potential future equity issuances under the shelf registration on earnings per share.
- Cash Position: Track the cash balance, which declined to $1.5 million, against the $5.0 million related-party note due in January 1998 and other short-term obligations.